News | November 01, 2022
Aptar Pharma completes Phase I global injectables expansion program
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Subscribe To Our Newsletter & Stay Updated
